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Abstract. Amplification of genes associated with cell control 
and differentiation is found in many human tumours and its 
detection may have important value in predicting tumour 
progression. In this study we examined 72 DNA samples 
extracted from paraffin-fixed formalin-embedded transitional 
cell carcinomas with a novel differential PCR technique that 
can detect variations in gene dosage using small amounts of 
tumour DNA. We have observed that this technique under 
certain conditions has many advantages over traditional gene 
analysis techniques. Our study revealed EGF-r and c-erbB-2 
gene amplification in 2/72 (3%) and 11/72 (15%) bladder 
carcinomas, respectively. EGF-r gene was amplified in 2/24 
(8%) grade III carcinomas while c-erbB-2 was amplified in 
2/25 (8%) and 9/24 (37.5%) grade II and grade III 
carcinomas, respectively. All cases with EGF-r and c-erbB-2 
gene increased copy number were classified as invasive on 
the basis of muscularis propia invasion. The association 
between c-erbB-2 amplification and tumour grade as well as 
stage of the carcinomas was statistically significant 
indicating direct linkage to bladder carcinoma progression, 
while the relationship between EGF-r gene amplification and 
the above mentioned parameters did not reach significance. 
Introduction 
Epidermal growth factor receptor and c-erbB-2 genes are 
located on chromosomes 7 locus p22-24ter and 17 locus q21, 
respectively. They encode transmembrane phospho-
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glycoproteins characterized by an extracellular domain which 
interacts with various growth factors, a transmembrane 
section and an intracellular domain with tyrosine kinase 
activity. EGF-r is stimulated by EGF, TGF-cc, and 
amphiregulin (1-5). This stimulation results in activation of 
cell growth regulation mechanisms (6). On the other hand the 
ligand which activates c-erbB-2 has not yet been identified 
(7,8), although recently a rat ligand has been identified (9). 
EGF-r and c-erbB-2 are expressed on cells derived from 
all three germ layers and expressed at particularly high levels 
on epithelia (10,11). Considering their wide tissue 
distribution, it is not surprising that EGF-r and c-erbB-2 are 
frequently expressed in human tumours. Interestingly, 
increased activity is most often due not to a structural 
abnormality but rather to overexpression of normal receptors 
(12). 
Overexpession of EGF-r and c-erbB-2 has been observed 
in squamous cell carcinomas and adenocarcinomas (10, Π­
Ι 6). One important mechanism of protein overproduction is 
gene amplification. EGF-r and c-erbB-2 gene amplification 
has been observed in human malignancies (13,19-21) and in 
certain cases related with adverse prognosis. 
The information regarding EGF-r and c-erbB-2 gene 
amplification in bladder carcinomas is limited. In order to 
evaluate the amplification of these genes in transitional cell 
bladder carcinomas (TCC) we analysed the DNA from 72 
carcinoma specimens with a novel PCR technique and 
correlated our findings with pathological features of the 
tumours. 
Materials and methods 
Tissue samples. Seventy-two cases of surgically removed and 
biopsy specimens formalin-fixed and paraffin-embedded 
transitional carcinoma of the bladder retrieved from the files 
of Red Cross Hospital, Athens were studied. Histologically 
they consisted of 23 grade I, 25 grade II and 24 grade III 
carcinoma cases (WHO classification 1973). Forty- four had 
superficial tumours (pTa and pTl) and 28 had muscle 
invasive disease. In addition, 29 samples from adjusted 
normal urothelium were examined. 
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DNA extraction from paraffin. The DNA extraction was 
performed on 5 μηι sections of the paraffin-embedded 
tumour tissue. Serial 5 μπι sections were processed and the 
first section was stained with hematoxylin and eosin to 
visualise the extent of the tumour cells within each sample. 
The boundaries of the malignant tissue were delineated 
microscopically and excess stromal tissue was excised from 
the paraffin sections on the slide using sterile surgical blades, 
in order to ensure that only neoplastic cells were included. 
The remaining neoplastic tissue was scraped with a sterile 
blade and wrapped with gauze, tied, placed into xylene and 
put in a 65°C waterbath for 10 min followed by 20 min in 
xylene at RT and then rinsed with 100% alcohol. Tissue 
sections were transferred to 20 ml polypropylene in Falcon 
tubes containing 4-12 ml of a lysis solution (as determined 
from the number of sections cut where the solution should 
cover the section completely). 
The lysis solution consistsed of 0.5% sodium dodecyl 
sulfate (SDS) and proteinase Κ (Boehringer), at a final 
concentration of 500 μg/ml from a 20 μg/ml stock in ddH20. 
The solution was buffered with TNE (0.05 M Tris HCl pH 
8.0, 0.15 M NaCl, 5 mM EDTA). Lysis was carried out in a 
45 °C waterbath with very gentle agitation. This procedure 
was carried out for 72 h with the addition of new proteinase 
Κ (250 μg/ml) on each successive day of lysis. The samples 
were then centrifuged (2.500 rpm, 10 min) in a bench 
Beckman centrifuge. The supernatant was extracted 3 times 
with equal volume of phenol. Then the aqueous phase was 
treated with RNAse A (Boehringer) at final concentration of 
100 μg/ml at 37°C for 30 min. The extraction continued with 
3 additional extractions with equal volumes of phenol: 
chloroforrmisoamyl alcohol (25:24:1) or until no middle-
phase was visible. After each addition of the organic solvent, 
the organic and aqueous phases were mixed with gentle 
inversion (samples were never mixed in the vortex to avoid 
mechanical stress) and were centrifuged (3.000 rpm, 10 min, 
RT) in a bench centrifuge. The upper (aqueous) phase was 
removed using a 1 ml blue tip, cut almost at the middle and 
placed in a new 50 ml sterile Falcon tube. 
After organic extraction the aqueous phase was 
transferred to dialysis membranes (Sigma) in order to remove 
most of the proteins with MW of 12 KDa or greater. The 
samples were dialyzed versus TE buffer (10 mM Tris HCl, 1 
mM EDTA, pH 8.0) in a 103 times larger volume, for 3 
successive changes (2.3 and 16 h, respectively). The dialysis 
was carried out at 4°C under continuous stirring. Following 
dialysis, the DNA in the TE solution was measured at OD260. 
The ratio OD260/OD280 was greater than 1.8. 
Differential polymerase chain reaction (DPCR). EGF-r and 
c-erbB-2 gene amplification was studied with differential 
PCR (17). The basis of differential PCR is the co-
amplification by PCR of a target gene and a reference gene in 
the same reaction vessel. If the target gene copy number is 
greater than that of the reference gene, the PCR product of 
the target gene will be over-represented and the PCR 
amplification of the reference gene will be suppressed. This 
method is reliable if certain factors are taken into 
consideration: (i) DNA degradation: DNA fragments less 
than 300 bp in size influence the results of DPCR (18). To 
avoid the fragmentation of DNA, we have used the modified 
DNA extraction method mentioned above. This method 
produces good quality of DNA (ii) Amount of tissue (17). 
Furthermore, we used an analytical algorithm to 
effectively eliminate any false-positive determination of gene 
amplification due to DNA fragmentation and the changing 
dynamics of the PCR itself (Fig. 1). 
The following analytical algorithm for the detection of 
gene amplification was used. First DPCR with two sets of 
primers specific for different exons of the same γ-IFN gene 
were co-amplified in the same reaction vessel, one set of 
amplimers resulting in a PCR product of 150 bp and the other 
set giving a 82 bp band. Imbalances in the PCR amplification 
of the yIFN150 and the yIFN82 fragments should not be 
caused by the presence of gene amplification and therefore 
can be used as an indirect measure of the quality of the target 
genomic DNA. Thus, for our studies paraffin sections giving 
YlFN82/yIFN150 ratios equal to 1 indicated that the sample 
could be further analyzed. Second, a DPCR with the 
predicted target gene product smaller than the reference gene 
product: EGF-r/ylFN 150 and c-erèB-2/yIFN150. Positive 
samples from this reaction should then be analyzed by a 
DPCR, giving a reference gene product that is smaller than 
the target gene EGF-r/yIFN85 and c-erèB-2/yIFN85. If this 
critical reaction is positive, indicating the presence of gene 
amplification, verification using each target gene as reference 
gene was employed (EGF-r/c-erbB-2). 
Specific DNA sequences (Table I) were amplified in a 
PCR mixture containing 1 μg of the target DNA sample, 50 
mM KCl, 10 mm Tris-HCl pH 8.3, 1.5 mm MgCl2, 0.25 mm 
of each dNTP, 20 pmol/μΐ of each amplimer and 2 Units of 
AmpliTaq polymerase (Perkin Elmer Cetus, Ca) in 100 μΐ. 
The reaction was overlaid with two drops of mineral oil 
(Sigma, St. Louis, MO) and placed into a DNA thermocycler 
480 (Perkin Elmer Cetus, Ca). The following protocol was 
used: 1st cycle 10 min at 94°C, 2-40 cycles 1 min at 94°C, 
50°C and 72°C respectively and last cycle 10 min at 72°C. 
Ten percent of each PCR reaction product was 
electrophoresed for 2 hours in a 12% Polyacrylamide gel and 
stained with ethidium bromide. The relative intensity of the 
bands was quantified using photograph negatives of the 
ethidium stained gels and densitometry was performed on a 
video image analysis system. The results are expressed as the 
ratio of: 
Relative intensity of target gene sample 
Relative intensity of reference gene sample 
The oligonucleotides used as primers (Table II) were 
synthesized -on a cyclone Plus Synthesizer (Milligan 
Bioresearch Mass, USA) by phosphoramidite chemistry and 
deprotected by treatment with NH 4 0 4 O/N at 55°C and OPC 
cartridge purification. 
Controls for DPCR. Cell lines A431 and MDA 361 which 
carry 15-20 fold EGF-r gene and 2-4 fold c-erbB-2 gene 
amplification, respectively were used as controls. 
Statistical analysis. Statistical analysis was carried out by 
chi-square test with Yale's correction and additional Fisher's 
exact test in certain correlations. 
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YIFN150 
=1 No amplification 
1-XiF-r c-crbB-2 — <1 Amplified 
YIFN150 YIFN150 
2) — or 
EGF-r c-erbB-2 
3) or 
YIFN85 
=1 No amplification 
>1 Amplified —*> Positive 
c-erbB-2 
=1 No relative amplification 
ρ\ Relatively amplified 
Figure 1. An analytical algorithm for the detection of EGF-r and c-erbB-2 gene amplification in archival tissue. 
Table I. Amplified sequences. Table II. Oligonucleotide primers. 
Gene Length of PCR-amplified 
sequence 
Sequence Ref. 
region no. 
Results 
The DNA obtained from the majority of the formalin-fixed 
samples (72 out of 75), was of high quality as assessed 
electrophoretically. The quality of DNA was also verified 
from the first PCR reaction of the algorithm: YlFN-150/yIFN-
82 which showed in most of the cases a ratio between 0.8 
and 1 (Fig. 2A,B). 
The DNA was then analysed with the differential PCR 
technique which revealed EGF-r and c-erbB-2 gene 
amplification in 2/72 (3%) and 11/72 (15%) bladder 
carcinomas respectively (Fig. 2D-H). EGF-r gene was 
amplified in 2/24 (8%) grade HI carcinomas while c-erbB-2 
was amplified in 2/25 (8%) and 9/24 (37.5%) grade II and III 
transitional cell bladder carcinomas, respectively (Table III 
and IV). In addition, all specimens with EGF-r and c-erbB-2 
gene amplification were tumours classified as invasive on the 
Primer sequence 
ΙΡΝγ 
IFNY 
IFNy 
EGF-r 
c-erbB-2 
150 bp 
82 bp 
85 bp 
110 bp 
98 bp 
4582-4731 
2012-2093 
4647-4731 
3801-4010 
2122-2213 
37 
37 
37 
38 
39 
ΙΡΝγ (150) 
IFNY (82) 
IFN (85) 
EGF-r 
5'-CTC TTT TCT TTC CCG ATA GGT-3' 
3'-CTG GGA TGC TCT TCG ACC TCG-5' 
5'-GCA GAG CCA AAT TGT CTC CT-3' 
3'-GGT CTC CAC ACT CTT TTG GA-5' 
5'-AGT GAT GGC TGA ACT GTC GC-3' 
3'-CTG GGA TGC TCT TCG ACC TC-5' 
5'-AGC CAT GCC CGC ATT AGC TC-3' 
3'-CAA AGG AAT GCA ACT TCC CA-5' 
5'-CCT CTG ACG TCC ATC ATC TC-3' 
3'-ATC TTC TGC TGC CGT CGC TT-5' 
c-erbB-2 
basis of muscularis propia invasion (Table V and VI). 
Statistical analysis revealed a strong correlation between c-
erbB-2 gene amplification and grade as well as stage of the 
carcinomas (P=7.7xl0"4 and P=2.5xl06 with Fisher's exact 
test respectively). The relationship between EGF-r gene 
amplification and grade as well as stage of the disease did.-not 
reach significance (P=0.11 and P=0.127 with Fisher's exact 
test respectively). 
Comparison between the positive cell lines (A431 and 
MDA 361) and the carcinomas with amplification showed a 
6 and 9 fold amplification for EGF-r gene and a 5- to 8 fold 
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IFN150 
IFN82 
y U W4 
1 2 3 14 15 
IFN150 
IFN82 
Β 
M *•"* *"* 
fc*4 *fc* Ί * " ^ 
49 50 51 52 53 55 57 61 
IFN150 
c-erbB-2 
IFN150 
EGF-r 
IFN150 
c-erbB-2 
IFN150 
EGF-r 
1 2 3 14 15 
I.J U U U L i 
1 2 3 14 15 
49 50 55 57 61 
c-erbB-2 
IFN85 
EGF-r 
IFN85 
c-erbB-2 
IFN85 
EGF-r 
IFN85 
y bu Hb 
1 2 3 3 14 15 
1 2 - 4 14 15 49 50 55 57 NC M 60 61 
EGF-r 
c-erbB-2 
EGF-r 
c-erbB-2 
1 2 3 14 15 49 5 0 5 5 57 60 61 
G H 
_ 
Figure 2. Analysis of EGF-r and c-erbB-2 gene amplification by differential polymerase chain reaction (DPCR). A, C, E, G: Samples No 1,2, 3, 14, 15 have 
no indication of EGF-r or c-erbB-2 gene amplification. In Fig. 2E the reactions c-erbB-2/ IFN85 and EGF-r/ IFN85 in sample 3 are shown side by side. B, D, 
F, H: Samples No 49, 50, 55, 57 with c-erbB-2 gene amplification and samples No 60 and 61 with the EGF-r gene amplified. Samples No 51 and 52 were 
discarded due to imbalances in the quality control reaction. NC = Negative Control (Normal Urothelium); M = Marker. 
INTERNATIONAL JOURNAL OF ONCOLOGY 4: 1191-1197, 1994 1195 
Table III. Relationship between EGF-r gene amplification 
and grade of the carcinomas. 
EFG-r gene amplification 
+ 
I 
23 
Grade 
II 
25 
III 
2 (8%) 
22 (92%) 
Table IV. Relationship between c-erbB-2 gene amplification 
and grade of the carcinomas. 
c-erbB-2 gene amplification 
+ 
I 
23 
Grade 
II 
2 (8%) 
23 (92%) 
III 
9 (38%) 
15 (62%) 
Table V. Relationship between EGF-r gene amplification 
and grading of muscle invasive and superficial tumours. 
EGF-r gene 
amplification 
+ 
Grade 
I II HI I 
Superficial 
23 23 (92%) -
II III 
Invasive 
2 (8%) 
2(8%) 22(92%) 
Table VI. Relationship between c-erbB-2 gene amplification 
and grading of muscle invasive and superficial tumours. 
c-erbB-2 gene 
amplification 
+ 
Grade 
I II III I 
Superficial 
23 23(92%) -
II III 
Invasive 
2 (8%) 9 (38%) 
15 (62%) 
for c-erbB-2 gene. The association between the degree of 
c-erbB-2 gene amplification, tumour grade and stage was 
also statistically significant (P<0.01). In addition no adjacent 
normal urothelium showed EGF-r or c-erbB-2 gene 
amplification. 
Discussion 
Quantitative and/or qualitative changes in the expression of 
oncogenes and their products are implicated in malignant 
transformation. There are several mechanisms which affect 
the function or expression of genes that control cell 
proliferation and differentiation (22). 
Gene amplification represents an important mechanism of 
genetic alteration leading to over-production of proteins 
encoded by these genes. It was first observed in cells selected 
for resistance to cytotoxic drugs in tissue culture. This led to 
the hypothesis that in some tumour cells amplification of 
specific genes may give them a selective growth advantage 
during chemotherapy. Direct evidence that this can occur, 
came from analysis of tumour cells taken from patients 
treated with methotrexate (23). Another set of genes often 
amplified in tumour samples are oncogenes. It has been 
proposed that the levels of amplification of these genes can 
correlate with progression to more malignant phenotypes and 
with patients prognosis (24). 
Type I growth factor receptors (EGF-r, c-erbB-2 and 
c-erbB-3) are a closely related group of molecules which are 
expressed widely in normal tissues. Deregulation of their 
expression seems to be involved in oncogenesis. The EGF-r 
is overexpressed and its gene is amplified in a wide range of 
carcinomas and sarcomas. Its expression has been shown to 
be of prognostic importance in predicting the biological 
behaviour of certain type of carcinomas (10,19,25,26). 
Overexpression of c-erbB-2 protein in human malignancies, 
a feature usually associated with c-erbB-2 amplification, has 
been related with adverse prognosis in breast and ovarian 
carcinomas (13,20,21). In this work we examined EGF-r and 
c-erbB-2 gene amplification in 72 transitional cell carcinoma 
of the urinary bladder and correlated the results with 
pathologic features of the tumours. 
For this purpose we analyzed the extracted DNA samples 
from our formalin fixed paraffin embedded samples with the 
differential PCR technique and a diagnostic algorithm. In a 
previous study we used the DPCR method and observed that 
under certain conditions, its sensitivity is comparable with 
that of Southern blot analysis (27). The advantages of DPCR 
over traditional gene analysis methods are: (i) the capability 
to examine larger numbers of samples in a shorter time 
period (maximum 2 days); (ii) the method is non-radioactive 
and (iii) using the appropriate controls, DPCR estimate can 
semi-quantitative gene dosages. 
By performing the DPCR technique on our bladder 
samples we found EGF-r and c-erbB-2 gene amplification in 
2/72 (3%) and 11/72 (15%) cases, respectively. The majority 
of the specimens with increased EGF-r and c-erbB-2 copy 
numbers were high grade and invasive (see Tables III-VI). In 
addition, degree of amplification was also higher in high 
grade and invasive carcinomas. These findings are in 
accordance with those of Berger et al, who observed a 8-10 
fold EGF-r gene amplification in 1/29 (3.5%) bladder 
carcinomas (28) and Coombs et al, who found that 12 out of 
86 (14%) transitional cell tumours had an amplified c-erbB-2 
gene (29). The latter study also indicated an association 
between degree of amplification and tumour grade. 
We also observed immunohistochemically a close 
relation between EGF-r and c-erbB-2 overexpression, grade 
and tumours stage. It is notable, that video image analysis 
showed in all cases where EGF-r and c-erbB-2 gene was 
amplified an increase of 10% for EGF-r and 25% for c-erbB-2 
of staining signal compared to the other specimens with 
overexpression of these molecules (unpublished data). It 
seems that c-erbB-2 gene amplification represents a frequent 
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and important mechanism of c-erbB-2 overexpression in 
transitional cell bladder carcinoma and is directly linked to 
tumour grade and progression. On the other hand EGF-r gene 
amplification is a less frequent event and possibly EGF-r 
overexpression in bladder tumours is a consequence of 
increased transcription. The latter hypothesis cannot be 
substantiated since our study was performed in formalin-
fixed material where mRNA analysis is not feasible. 
There are several reports which address the concept of 
various proto-oncogenes in the pathogenesis and prognosis of 
transitional cell bladder carcinoma, but their role remains still 
unclear (30-32). Recent ly , Dalbagni et al p roposed a 
sequence of genetic events which lead to bladder tumour 
progression and are correlated with pathological indices of 
poor clinical outcome (33). It is possible that these genetic 
events may lead to secondary deregulation of growth factor 
receptor expression. The deregulation of growth factor 
receptor expression (overexpression, autocrine stimulation) 
in condit ional renewal t issues is sufficient for tumour 
initiation, but in renewal tissue such as urothelium, molecular 
lesions which simply shorten cell cycle time would not be 
adequate to initiate tumorigenesis (34). In renewal tissue the 
expected initial molecular lesion is one which inactivates the 
decycling/terminal differentiation mechanism, for example 
loss of anti-oncogene p53 activity rather than positive 
autocrine growth signals. Therefore EGF-r and c-erbB-2 
overexpression and gene amplification possibly represent late 
events in bladder oncogenesis although there are reports on 
morphologically normal and hyperplastic cells from the 
b l a d d e r o v e r e x p r e s s i n g the c-erbB-2 p r o d u c t (29) . 
Furthermore, the simultaneous expression pattern of EGF-r 
and c-erbB-2 in the majority of the specimens we examined 
(unpublished data) could indicate that c-erbB-l (EGF-r) and 
c-erbB-2 form heterodimeric receptors, a phenomenon 
observed in vitro (35). These heterodimeric receptors have 
particularly high affinity for EGF, which is found in very 
high concentrations in urine (80 ng/ml) (36). 
Further evaluation is required to clarify these hypotheses 
which may allow us to predict prognosis of bladder cancer 
more accurately. 
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